CN111542744A

CN111542744A - Blood analyzer, blood analysis method, and computer-readable storage medium

Info

Publication number: CN111542744A
Application number: CN202080001015.3A
Authority: CN
Inventors: 祁欢; 苟理尧; 潘世耀; 肖建萍; 王官振; 叶波; 叶燚
Original assignee: Shenzhen Mindray Bio Medical Electronics Co Ltd
Current assignee: Shenzhen Mindray Bio Medical Electronics Co Ltd
Priority date: 2020-03-10
Filing date: 2020-03-10
Publication date: 2020-08-14
Anticipated expiration: 2040-03-10
Also published as: CN111542744B; WO2021179177A1

Abstract

The embodiment of the invention discloses a blood analyzer, a blood analysis method and a readable storage medium for prompting a novel coronavirus infection sample according to blood conventional parameters. The blood analyzer includes: the sampling device is used for sucking a blood sample to be detected; the sample preparation device is used for preparing a sample liquid to be detected from a blood sample to be detected and the processing reagent; the detection device is used for detecting the sample liquid to be detected so as to obtain blood conventional parameters; display means for displaying information relating to blood routine parameters; and the control device is configured for acquiring analysis parameters related to the novel coronavirus infection from the blood conventional parameters of the blood sample to be detected, and controlling the display device to display alarm information related to the novel coronavirus infection when the analysis parameters meet preset conditions. The implementation of the invention can realize low cost and fast output of the information related to the novel coronavirus infection and alarm.

Description

Blood analyzer, blood analysis method, and computer-readable storage medium

Technical Field

The embodiment of the invention relates to the field of blood detection, in particular to a blood analyzer, a blood analysis method and a computer readable storage medium for prompting a novel coronavirus infection sample according to blood conventional parameters.

Background

In the early 2020, infectious diseases caused by the novel coronavirus 2019-nCoV, also known as novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19), developed in China. The novel coronavirus belongs to the genus beta coronavirus, has envelope, and has round or elliptical particle, usually polymorphism, and diameter of 60-140 nm. The gene characteristics of 2019-nCoV are obviously different from those of SARSr-Cov and MERSR-CoV. The present research shows that the homology between 2019-nCoV and bat SARS-like coronavirus (bat-SL-CoVZC45) is up to 85% or more. In vitro isolation culture can be found in human respiratory epithelial cells within about 2019-nCoV 96 hours, while in Vero E6 and Huh-7 cell lines, isolation culture takes about 6 days.

In the diagnostic criteria for the novel coronavirus pneumonia, the need for real-time fluorescent RT-PCR detection or virus gene sequencing is clearly suggested. However, nucleic acid detection and gene sequencing take a long time, typically one day, and therefore may result in further viral transmission in suspected patients due to an inability to timely diagnose whether the suspected patient is infected with the novel coronavirus pneumonia.

Disclosure of Invention

Therefore, in view of the above situation, an object of the embodiments of the present invention is to provide a solution capable of prompting a new coronavirus infection sample according to blood general parameters at low cost and quickly, in which the existing blood general parameters of a blood cell analyzer can be used to perform early warning on the new coronavirus infection sample, assist medical staff to quickly judge whether a suspected patient may be infected with the new coronavirus, and even judge the infection degree, so that the medical staff can make a quick response in advance to prevent the virus from further spreading. In addition, the solution does not need additional test cost, and can realize the early warning of the novel coronavirus infection sample while utilizing the conventional hemocytometer to carry out conventional blood detection.

The invention provides a blood analyzer for prompting a novel coronavirus infection sample according to blood conventional parameters, which comprises: a sampling device which is provided with a pipette nozzle and a driving part, wherein the driving part is used for driving the pipette to quantitatively suck a blood sample to be measured through the pipette nozzle; a sample preparation device having at least one reaction cell for receiving a blood sample to be tested drawn by the sampling device and a reagent supply portion that supplies a treatment reagent to the at least one reaction cell, so that the blood sample to be tested drawn by the sampling device and the treatment reagent supplied by the reagent supply portion are mixed in the reaction cell to prepare a sample liquid to be tested; the detection device is used for detecting the sample liquid to be detected prepared by the sample preparation device so as to obtain blood conventional parameters; display means for displaying information relating to blood routine parameters; and a control apparatus comprising a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: and obtaining analysis parameters related to the novel coronavirus infection from the blood conventional parameters of the blood sample to be detected, and controlling the display device to display alarm information related to the novel coronavirus infection when the analysis parameters meet preset conditions.

In a second aspect, the present invention provides a blood analyzer capable of operating in a blood routine test mode or a novel coronavirus infection test mode, comprising: a sampling device which is provided with a pipette nozzle and a driving part, wherein the driving part is used for driving the pipette to quantitatively suck a blood sample to be measured through the pipette nozzle; a sample preparation device having at least one reaction cell for receiving a blood sample to be tested drawn by the sampling device and a reagent supply portion that supplies a treatment reagent to the at least one reaction cell, so that the blood sample to be tested drawn by the sampling device and the treatment reagent supplied by the reagent supply portion are mixed in the reaction cell to prepare a sample liquid to be tested; the detection device is used for detecting the sample liquid to be detected prepared by the sample preparation device so as to obtain blood conventional parameters; display means for displaying information relating to blood routine parameters; the mode setting device is used for setting a blood routine mode or a novel coronavirus infection alarm mode; and a control apparatus comprising a processor and a storage medium storing a computer program, wherein the control apparatus is configured to perform the following steps when the computer program is executed by the processor:

controlling the sampling means, the sample preparation and the action of the detection means so as to obtain only analysis parameters related to a novel coronavirus infection when a novel coronavirus infection detection mode is set by the mode setting means,

and when the analysis parameters meet preset conditions, controlling the display device to display alarm information related to the novel coronavirus infection.

In a third aspect, the present invention provides a method for analyzing blood for a sample indicative of a novel coronavirus infection based on blood general parameters, the method comprising the steps of: providing a blood analyzer; sucking a blood sample to be tested by a sampling distribution device of a blood analyzer; mixing a part of the blood sample to be tested with a treatment reagent in at least one reaction cell of a blood analyzer to prepare a sample liquid to be tested; detecting blood cells in the sample liquid to be detected in a detection device of a blood analyzer to obtain blood conventional parameters; obtaining analysis parameters related to the novel coronavirus infection from blood conventional parameters of the blood sample to be tested; and when the analysis parameters meet preset conditions, displaying information related to the novel coronavirus infection on a display device of the blood analyzer.

A fourth aspect of the present invention provides a computer-readable storage medium for a blood analyzer, the computer-readable storage medium having a computer program stored thereon, the computer program when executed by a processor implementing the steps of: obtaining blood conventional parameters of a blood sample to be detected, which are detected by a detection device of a blood analyzer; obtaining analysis parameters related to the novel coronavirus infection from blood conventional parameters of the blood sample to be tested; when the analysis parameters satisfy a preset condition, indicating to display information related to the novel coronavirus infection on a display device of the blood analyzer.

Drawings

FIG. 1 is a schematic diagram of a blood analyzer according to an embodiment of the present invention;

FIG. 2 is a schematic view of an optical detection unit according to an embodiment of the present invention;

fig. 3 is a schematic diagram of an impedance detecting unit according to an embodiment of the present invention;

fig. 4 is a schematic diagram of a control device according to an embodiment of the present invention;

FIG. 5 is a schematic representation of a generalized ROC curve;

FIG. 6 is a ROC curve for alarming a sample positive for a new coronavirus infection using a single blood routine parameter, provided by an embodiment of the present invention;

FIG. 7 is a ROC curve for alarming a sample positive for a new coronavirus infection using a linear combination of two blood routine parameters, provided by an embodiment of the present invention;

FIG. 8 is a ROC curve for alarming a sample positive for a new coronavirus infection using a non-linear combination of two blood routine parameters, provided by an embodiment of the present invention;

FIG. 9 is a ROC curve for warning of the extent of infection by a new coronavirus using a single blood routine parameter as provided by an embodiment of the present invention;

FIG. 10 is a ROC curve for warning of the extent of infection by a new coronavirus using a linear combination of two blood routine parameters, as provided by an embodiment of the present invention;

FIG. 11 is a ROC curve for warning of the extent of infection by a new coronavirus using a non-linear combination of two blood routine parameters, as provided by an embodiment of the present invention;

FIG. 12 is a ROC curve for warning prognosis of patients with new coronavirus infection using a single blood routine parameter, provided by an embodiment of the present invention;

FIG. 13 is a ROC curve for warning of prognosis of patients with new coronavirus infection using a linear combination of two blood routine parameters as provided by an embodiment of the present invention;

FIG. 14 is a ROC curve for warning of prognosis of patients with new coronavirus infection using a linear combination of three blood routine parameters as provided by an embodiment of the present invention;

FIG. 15 is a ROC curve for warning of prognosis of patients with new coronavirus infection using a non-linear combination of two blood routine parameters as provided by an embodiment of the present invention;

FIG. 16 is a schematic flow chart of a method of a hematology analyzer for alerting of new coronavirus infection using blood flow parameters, provided by an embodiment of the present invention.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.

It should be noted that, in the embodiments of the present invention, the terms "comprises", "comprising" or any other variation thereof are intended to cover a non-exclusive inclusion, so that a method or apparatus including a series of elements includes not only the explicitly recited elements but also other elements not explicitly listed or inherent to the method or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other related elements in a method or apparatus including the element (e.g., steps in a method or elements in an apparatus, such as a part of a circuit, a part of a processor, a part of a program or software, etc.).

It should be noted that the terms "first \ second \ third" related to the embodiments of the present invention only distinguish similar objects, and do not represent a specific ordering for the objects, and it should be understood that "first \ second \ third" may exchange a specific order or sequence when allowed. It should be understood that the terms first, second, and third, as used herein, are interchangeable under appropriate circumstances such that the embodiments of the invention described herein are capable of operation in other sequences than those illustrated or otherwise described herein.

In the present embodiment, ROC is an abbreviation of Receiver operating characteristics of a subject. ROC analysis can be used for medical decision evaluation, such as for diagnostic radiology, laboratory medicine, screening for cancer, and diagnosis of psychosis, particularly for the evaluation of the accuracy of medical imaging diagnosis. As understood by those skilled in the art, the ROC curve mainly relates to the plotting of the ROC curve, the calculation of AUC and the selection of an optimal working point. The ROC curve is calculated for all possible thresholds, and each threshold calculates a corresponding TPR (true positive rate, i.e., sensitivity, TPR ═ true positive count/positive count) and FPR (false positive rate, i.e., 1-specificity, FPR ═ false positive count/negative count). Thus, pairs of TPR and FPR values are obtained, and then an ROC curve is plotted with FPR as the x-axis (i.e., abscissa) and TPR as the y-axis (i.e., ordinate), where the abscissa has a minimum value of 0 and a maximum value of 1. A typical ROC curve is shown in FIG. 5, where the dashed black line is the ROC curve. The ROC curve can characterize the correlation between sensitivity and specificity, and thus can reflect the efficacy of a diagnostic system dynamically and objectively. AUC is the Area (Area Under the curve) enclosed by the ROC curve and the x-axis (FPR), and the gray Area in FIG. 5 is shown as AUC, and the ideal AUC is 1, and the lowest is 0.5. The greater the AUC, the better the classification effect of the representative model, and the more accurate the detection of the disease. The selection of the optimal operating point is to determine the optimal combination of TPR and FRP on the selected ROC curve, the point of the curve with the maximum TPR and the minimum FPR is the optimal operating point, and the selection of the optimal operating point is more common: a positive likelihood ratio method, a Youden index method (Youden index method), a method of maximizing the sum of squares of sensitivity and specificity, and the like.

It is understood that the blood routine examination is a method of examining the number, ratio, and morphology of various blood cells in the peripheral blood of a human body by a blood cell analyzer. A Blood Cell analyzer is an instrument capable of detecting cells in Blood, and can count and classify particles in Blood, such as White Blood Cells (WBC), Red Blood Cells (RBC), Platelets (PLT), Nucleated Red Blood Cells (NRBC), reticulocytes (Ret), and the like, that is, Blood routine examination. The blood routine examination has a diagnosis reference value, and many patients can make the blood routine examination to perform auxiliary diagnosis when the etiology is unknown. In addition, routine blood tests are common indicators of observed therapeutic effects, medication or withdrawal, continued or discontinued therapy, recurrence or recovery of disease.

The blood cell analyzer can give the following reported parameters and study parameters as shown in tables 1 and 2 below. In the embodiment of the present invention, the white blood cell parameter is a white blood cell-related parameter obtained by the blood analyzer, the red blood cell parameter is a red blood cell-related parameter obtained by the blood analyzer, the platelet parameter is a platelet-related parameter obtained by the blood analyzer, and the hemoglobin parameter is a hemoglobin-related parameter obtained by the blood analyzer.

TABLE 1 blood test report parameters description table

TABLE 2 blood test study parameter description Table

Since the blood routine parameters, such as the white blood cell count or lymphocyte count/ratio, of the new coronavirus infection positive blood sample are subject to a specific change compared to the negative sample, the specific change can indicate that the blood sample is likely to be a new coronavirus infection positive sample, and can even indicate the degree or development trend of the new coronavirus infection. Based on the above, the embodiment of the invention provides a solution for prompting a novel coronavirus infection sample according to blood general parameters. The solution provided by the embodiment of the invention has the advantages of high speed and low cost, namely, the blood routine can be finished within 15 minutes from the collection to the test completion fastest, the blood routine detection charge is low, and the nucleic acid detection needs one day to obtain the result.

The embodiment of the invention firstly provides a blood analyzer for alarming a new coronavirus infection sample according to blood conventional parameters. As shown in fig. 1, the blood analyzer 100 includes at least a sampling device 110, a sample preparation device 120, a detection device 130, a display device 140, and a control device 150.

The sampling device 110 has a pipette (e.g., a sampling needle) with a pipette nozzle and a driving unit for driving the pipette to quantitatively take a blood sample to be measured through the pipette nozzle, for example, the sampling needle is moved by the driving unit to take the blood sample to be measured from a sample container containing the blood sample.

The sample preparation device 120 has at least one reaction cell and a reagent supply device (not shown). The at least one reaction cell is used for receiving a blood sample to be tested, which is drawn by the sampling device 110, and the reagent supply device provides a treatment reagent to the at least one reaction cell, so that the blood sample to be tested, which is drawn by the sampling device 110, and the treatment reagent provided by the reagent supply device are mixed in the reaction cell to prepare a sample solution to be tested. In some embodiments, the reagent supply comprises a first reagent supply for supplying a leukocyte reagent, for example comprising a haemolysing agent capable of lysing red blood cells in a blood sample and of differentiating between different leukocyte types, optionally also comprising a fluorescent reagent capable of staining leukocytes. In some embodiments, the reagent supply device comprises a second reagent supply for supplying a red blood cell reagent, such as a diluent. In other embodiments, the reagent supply device includes a third reagent supply for supplying a hemoglobin reagent, such as a hemolytic agent capable of lysing red blood cells in the blood sample, releasing hemoglobin in the red blood cells, and converting hemoglobin into methemoglobin. In some embodiments, the leukocyte reagent and the hemoglobin reagent are the same hemolytic agent, i.e., the first reagent supply and the third reagent supply are the same reagent supply.

The detecting device 130 is used for detecting the sample liquid to be detected prepared by the sample preparation device 120 to obtain the blood routine parameters.

In some embodiments, the detecting device 130 has an optical detecting portion 131 for detecting a first sample liquid to be tested prepared from a portion of the blood sample to be tested and a leukocyte reagent supplied from the first reagent supplying portion to obtain a leukocyte parameter, optionally a platelet parameter. As shown in fig. 2, the optical detection section 131 has a light source 1311, a beam shaping member 1312, a flow cell 1313, and a forward scattered light detector 1314, which are arranged in this order on a straight line. On one side of flow chamber 1313, a dichroic mirror 1316 is arranged at an angle of 45 ° to the straight line. A portion of the side light emitted by blood cells in flow chamber 1313 is transmitted through dichroic mirror 1316 and captured by fluorescence detector 1315 disposed behind dichroic mirror 1316 at a 45 ° angle to dichroic mirror 1316, while another portion of the side light is reflected by dichroic mirror 1316 and captured by side scatter detector 1317 disposed in front of dichroic mirror 1316 at a 45 ° angle to dichroic mirror 1316. From the forward scattered light signal captured by forward scatter light detector 1314, the side scattered light signal captured by side scatter light detector 1317, and the fluorescence signal captured by fluorescence detector 1315, leukocytes in the blood sample can be counted and classified, for example, into at least neutrophils, lymphocytes, and monocytes, and optionally platelet parameters, such as the number of platelets obtained, in the blood sample can be further detected.

In some embodiments, the detecting device 130 includes an impedance detecting part 132, and the impedance detecting part 132 is used for detecting a second sample liquid to be tested prepared by a part of the blood sample to be tested and the red blood cell reagent supplied from the second reagent supplying part to obtain the red blood cell parameter and the platelet parameter. For example, the impedance detecting section 132 is configured as a sheath flow impedance detecting section, and as shown in fig. 3, the sheath flow impedance detecting section 132 includes a flow cell 1321 having a hole 1322 with an electrode 1323. The sheath flow impedance detecting unit 132 detects a direct current impedance generated when the particles in the sample liquid to be measured pass through the hole 1322, and outputs an electric signal reflecting information when the particles pass through the hole. Specifically, the sampling device 110 is driven by its driving means and moved to the reaction cell of the sample preparation device 120 after the blood sample is drawn, and the drawn blood sample is injected into the reaction cell. The transfer line transfers the sample liquid to be measured after the dilution treatment in the reaction cell to the sheath flow impedance detecting unit 132, that is, to the flow cell 1321. The sheath flow impedance detecting unit 132 may be provided with a sheath liquid chamber, not shown, for supplying the sheath liquid to the flow chamber 1321. In the flow chamber 1322, the sample liquid to be measured flows through the sheath liquid under the encapsulation, and the small hole 1322 changes the sample liquid flow to a trickle, so that particles (formed components) contained in the sample to be measured pass through the small hole 1322 one by one. The electrode 1323 is electrically connected to a dc power source 1324, and the dc power source 1324 supplies dc power between the pair of electrodes 1323. While the dc power is supplied from the dc power supply 1324, the impedance between the pair of electrodes 1323 can be detected. The resistance signal representing the impedance change is amplified by the amplifier 1325 and sent to the control device 150. The magnitude of the resistance signal corresponds to the volume (size) of the particles, and therefore the red blood cell parameter and the platelet parameter of the sample liquid to be measured can be obtained by signal processing of the resistance signal by the control device 150.

In some embodiments, the detecting device 130 further includes a colorimetric detecting unit 133, and the colorimetric detecting unit 133 is configured to detect a third sample solution to be tested prepared from a portion of the blood sample to be tested and the hemoglobin reagent supplied from the third reagent supplying unit to obtain the hemoglobin parameter.

The display device 140 is used to display information related to blood general parameters. For example, the display device 140 is configured as a user interface.

In some embodiments, the control apparatus 150 comprises a processor and a storage medium storing a computer program configured to, when executed by the processor, perform the steps of: obtaining analysis parameters related to the novel coronavirus infection from blood conventional parameters of the blood sample to be tested; and when the analysis parameters meet the preset conditions, controlling the display device 140 to display alarm information related to the novel coronavirus infection. Further, the control arrangement 150 is further configured for controlling the display device 140 to display blood routine parameters of the blood sample to be tested, in particular for obtaining analysis parameters related to a novel coronavirus infection. That is, the control device 150 is configured to display alarm information related to the novel coronavirus infection while controlling the display device 140 to display the blood routine parameters of the blood sample to be tested.

Alternatively, in other embodiments, the blood analyzer 100 may further include a mode setting device, not shown, for setting a blood routine detection mode or a novel coronavirus infection detection mode. Here, the control device 150 comprises a processor and a storage medium storing a computer program, the control device 150 being configured to perform the following steps when the computer program is executed by the processor: when the novel coronavirus infection detection mode is set by the mode setting means, controlling the operations of the sampling means 110, the sample preparation 120 and the detection means 130 so as to acquire only analysis parameters related to the novel coronavirus infection; when the blood routine test mode is set by the mode setting means, the operations of the sampling means 110, the sample preparation 120 and the test means 130 are controlled to obtain blood routine parameters. That is, the blood analyzer 100 can be selectively operated in a blood routine detection mode or a novel coronavirus infection detection mode. In the novel coronavirus infection detection mode, the blood analyzer only acquires analysis parameters related to the novel coronavirus infection; in the blood routine test mode, the blood analyzer obtains general blood routine parameters. Further, the control device 150 is configured to control the display device 140 to display alarm information related to the new coronavirus infection when the analysis parameter satisfies a preset condition. Further, when the blood routine mode is set by the mode setting means, the control means is configured to control the display means 140 to display at least one blood routine parameter. As will be appreciated by those skilled in the art, the routine blood test mode is understood to be the test mode that is available with existing blood analyzers.

In some embodiments, as shown in FIG. 4, control device 150 includes at least a processing component 151, RAM152, ROM153, a communication interface 154, memory 156, and an I/O interface 155. Processing component 151, RAM152, ROM153, communication interface 154, memory 156, and I/O interface 155 communicate over a bus 157. The processing component may be a CPU, GPU or other chip with computing capabilities. The memory 156 stores various computer programs such as an operating system and an application program to be executed by the processor unit 151, and data necessary for executing the computer programs. In addition, data stored locally during the blood sample analysis may be stored in the memory 156, if desired. The I/O interface 155 is constituted by a serial interface such as USB, IEEE1394, or RS-232C, a parallel interface such as SCSI, IDE, or IEEE1284, and an analog signal interface composed of a D/a converter and an a/D converter. The I/O interface 155 is connected to an input device including a keyboard, a mouse, a touch panel, or other control buttons, and a user can directly input data to the control apparatus 150 using the input device. Further, a display device 140 having a display function, for example: liquid crystal screens, touch screens, LED display screens and the like. The control device 150 may output the processed data as image display data to the display device 140 for display, for example: analytical data, instrument operating parameters, etc. Communication interface 154 is an interface that may be any communication protocol currently known. The communication interface 154 communicates with the outside world via a network. Control device 150 may communicate data with any device connected via the network via communication interface 154 in a communication protocol.

In some embodiments, as shown in fig. 1, the blood analyzer 100 further includes a first housing 160 and a second housing 170. The detecting device 130 and the controlling device 150 are disposed inside the second housing 170, and disposed at both sides of the second housing 170, respectively. The sample preparation device 120 is disposed inside the first housing 160. The display device 140 is disposed on an outer surface of the first housing 160.

In some embodiments, the blood analyzer 100 further comprises a blood sample dispensing device (not shown) for separating the blood sample to be tested drawn by the sampling device 110 into at least two different blood samples for preparing a sample solution to be tested for detecting different blood parameters. For example, the blood sample distribution device is used for dividing a blood sample to be tested into a first blood sample and a second blood sample, a first sample liquid to be tested for white blood cell detection is prepared from the first blood sample and a white blood cell reagent, a second sample liquid to be tested for red blood cell detection is prepared from the second blood sample and a red blood cell reagent, and a third sample liquid to be tested for hemoglobin detection is optionally prepared from the first blood sample or the second blood sample and a hemoglobin reagent. Alternatively, the blood sample distribution device is used for dividing the blood sample to be tested into a first blood sample, a second blood sample and a third blood sample, the first sample liquid to be tested for detecting white blood cells is prepared from the first blood sample and a white blood cell reagent, the second sample liquid to be tested for detecting red blood cells is prepared from the second blood sample and a red blood cell reagent, and the third sample liquid to be tested for detecting hemoglobin is prepared from the third blood sample and a hemoglobin reagent. The blood sample distribution device can be designed, for example, as a blood distribution valve. Alternatively, the blood sample distribution device may be a sampling needle of the sampling device 110, in which case the driving part of the sampling device 110 drives the sampling needle to move to the position of different reaction cells of the sample preparation device 120, so as to respectively distribute a part of the blood sample to be tested to different reaction cells to react with the corresponding processing reagent.

In some embodiments, the analysis parameters comprise at least two blood routine parameters, or comprise a combined parameter of at least two blood routine parameters, such as a linear or non-linear combined parameter. In these embodiments, the control device 150 controls the display device 140 to display the warning information related to the new coronavirus infection when at least two blood routine parameters respectively satisfy the corresponding predetermined conditions or one parameter combined from at least two blood routine parameters satisfies the predetermined conditions.

In some embodiments, the analysis parameter comprises at least one of a white blood cell parameter, a red blood cell parameter, a platelet parameter, and a hemoglobin parameter, for example the analysis parameter comprises at least one white blood cell parameter or at least one red blood cell parameter or at least one platelet parameter or at least one hemoglobin parameter.

In some embodiments, the analysis parameter comprises a combination of a plurality of parameters selected from the group consisting of a white blood cell parameter, a red blood cell parameter, a platelet parameter, and a hemoglobin parameter. For example, the analysis parameters include a combination of multiple white blood cell parameters or a combination of multiple red blood cell parameters or a combination of multiple platelet parameters. For example, the analysis parameter comprises a combination of at least one white blood cell parameter and at least one red blood cell parameter or a combination of at least one white blood cell parameter and at least one platelet parameter or a combination of at least one red blood cell parameter and at least one platelet parameter or a combination of at least one white blood cell parameter, at least one red blood cell parameter and at least one platelet parameter.

Further, the analysis parameter comprises at least one of the following blood routine parameters or a combination, e.g. a linear or a non-linear combination parameter, of a plurality of the following blood routine parameters: white blood cell count, neutrophil number, neutrophil percentage, lymphocyte number, lymphocyte percentage, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, erythrocyte distribution width coefficient of variation, erythrocyte distribution width standard deviation, erythrocyte number, macrocyte ratio, microcyte ratio, platelet distribution width standard deviation, mean platelet volume, macrocyte ratio, high fluorescence intensity cell percentage, mean erythrocyte hemoglobin concentration, hemoglobin concentration.

Preferably, the analysis parameter comprises at least one of the following blood routine parameters and a combination of a plurality of the following blood routine parameters: the ratio of the neutrophils to the lymphocytes, the percentage of the lymphocytes, the variation coefficient of the distribution width of the erythrocytes, the standard deviation of the distribution width of the erythrocytes and the percentage of cells with high fluorescence intensity.

During the process of researching the blood routine parameters of a large number of novel coronavirus infection samples, the inventor finds that the parameters related to the distribution width of red blood cells have better alarm effectiveness for the novel coronavirus infection sample alarm. Thus, in some embodiments, the analysis parameter comprises at least one erythrocyte distribution width parameter, in particular a erythrocyte distribution width coefficient of variation or an erythrocyte distribution width standard deviation, or a erythrocyte distribution width coefficient of variation and an erythrocyte distribution width standard deviation. In some embodiments, the analysis parameters include a combination of at least one red blood cell distribution width parameter and at least one additional blood routine parameter, including, for example, a neutrophil to lymphocyte ratio, a lymphocyte percentage, or a high fluorescence intensity cell percentage. Therefore, the alarm of the novel coronavirus infection sample can be given by using the erythrocyte distribution width parameter.

During the process of researching the blood routine parameters of a large number of novel coronavirus infection samples, the inventor finds that the ratio of neutrophils to lymphocytes is particularly beneficial to alarm the novel coronavirus infection samples in combination with other blood routine parameters. Thus, preferably, the analysis parameters comprise a combination of a neutrophil to lymphocyte ratio and at least one further blood routine parameter. The at least one further blood condition parameter comprises, for example, at least one erythrocyte parameter, in particular an erythrocyte distribution width parameter (for example an erythrocyte distribution width coefficient of variation or an erythrocyte distribution width standard deviation).

In some embodiments, the alert information related to the novel coronavirus infection comprises alert information for prompting the blood sample to be tested to be a positive sample of the novel coronavirus infection. For example, when the analysis parameter meets a first preset condition, displaying an alarm message for prompting that the blood sample to be tested is a new coronavirus infection positive sample on a display device of a blood analyzer. In these embodiments, the test blood sample can be a blood sample from a patient suspected of being infected with the novel coronavirus.

In the case that the blood analyzer provided by the embodiment of the present invention is used for outputting an alarm message indicating that the blood sample to be tested is a new coronavirus infection positive sample, it is particularly advantageous that the analysis parameter includes at least one of the following blood conventional parameters or a combination, such as a linear or nonlinear combination parameter, of a plurality of the following blood conventional parameters: white blood cell count, lymphocyte percentage, neutrophil to lymphocyte ratio, red blood cell distribution width parameter (e.g. red blood cell distribution width coefficient of variation). Of course, the analysis parameters may also comprise a combination of at least one of the above blood-normal parameters and a plurality of the above blood-normal parameters. Preferably, the analysis parameter comprises a red blood cell distribution width parameter, in particular a red blood cell distribution width coefficient of variation. In some embodiments, the analysis parameters may also include a combination of a neutrophil to lymphocyte ratio and a red blood cell distribution width parameter, particularly a red blood cell distribution width coefficient of variation.

As shown in fig. 6 to 8, the inventors studied the efficacy of performing a positive alarm of a novel coronavirus infection on 318 blood samples, wherein the novel coronavirus infection positive samples comprise 156 samples and the negative samples comprise 162 samples, by using one or more parameters selected from the group consisting of white blood cell count WBC, lymphocyte percentage LYM%, neutrophil-lymphocyte ratio NLR, and erythrocyte distribution width variation coefficient RDW _ CV. Fig. 6 shows ROC curves for carrying out positive alarms on novel coronavirus infection by using the white blood cell count WBC, the lymphocyte percentage LYM, the neutrophil-lymphocyte ratio NLR, and the erythrocyte distribution width variation coefficient RDW _ CV, respectively, and it can be seen from fig. 6 that the alarm effect by using the erythrocyte distribution width variation coefficient RDW _ CV alone is AUC of 0.78, the specificity of 63%, the sensitivity of 78.8%, and the effect is better. Fig. 7 is a ROC curve for positive warning of new coronavirus infection using a linear combination of WBC and LYM% and a linear combination of NLR and RDW _ CV, and it can be seen from fig. 7 that the AUC of the linear combination parameters of NLR and RDW _ CV (linear combination formula such as 0.0585 NLR-0.352 RDW _ CV +4.6641) can reach 0.83 (specificity of 69.1%, sensitivity of 80.1%), which is significantly better than the parameter combination of WBC and LYM% (AUC of 0.71, specificity of 67.3%, sensitivity of 63.5%). FIG. 8 is a ROC curve for a positive alarm of new coronavirus infection using a nonlinear combination of NLR and RDW _ CV, where AUC is 0.82, specificity is 71.6%, sensitivity is 72.4%, and the formula for the nonlinear combination of NLR and RDW _ CV is as follows:

-0.3332*NLR+46.1415*RDW_CV+0.0186NLR.^2+0.0165*NLR*RDW_CV-1.8844*RDW_CV.^2-281.615。

in the embodiment of the invention, a Linear Discriminant Analysis (LDA) method is selected for linear combination analysis, and a QDA (quantitative Discriminant analysis) method is selected for nonlinear combination analysis.

Some blood routine parameters of patients with new coronary pneumonia have different numerical characteristics due to different infection degrees, such as normal or reduced total white blood cell count, decreased lymphocyte count and the like in early onset. Thus, in some embodiments, the alert information associated with the novel coronavirus infection comprises an alert information for indicating the degree of the novel coronavirus infection of the blood sample to be tested. For example, when the analysis parameter satisfies a second preset condition, displaying an alarm message for prompting the infection degree of the novel coronavirus of the blood sample to be tested on a display device of the blood analyzer. The degree of infection by the novel coronavirus includes mild and severe symptoms. That is to say, the blood analyzer provided by the embodiment of the present invention can not only alarm whether the blood sample is a novel coronavirus positive sample, but also further alarm the infection degree of the novel coronavirus positive sample. In this case, the test blood sample is preferably a blood sample of a patient infected with the novel coronavirus.

Advantageously, the analysis parameter comprises at least one of the following blood-specific parameters or a combined parameter, for example a linear or nonlinear combined parameter, of a plurality of the following blood-specific parameters: white blood cell count, lymphocyte percentage, neutrophil percentage, platelet to lymphocyte ratio, red blood cell distribution width parameter (e.g., red blood cell distribution width standard deviation), red blood cell number. Of course, the analysis parameters may also comprise a combination of at least one of the above blood-normal parameters and a plurality of the above blood-normal parameters. Preferably, the analysis parameter comprises lymphocyte percentage. Further preferably, the analysis parameters comprise a combination parameter, in particular a linear combination parameter, of the percentage of lymphocytes and a red blood cell distribution width parameter, in particular a standard deviation of the red blood cell distribution width. In some embodiments, the analysis parameters may also include a combination of neutrophil to lymphocyte ratio and number of red blood cells, in particular a non-linear combination.

As shown in fig. 9 to 11, the inventors studied the efficacy of alarming the degree of novel coronavirus infection on 239 samples positive for novel coronavirus infection by using one or a combination of parameters of white blood cell count WBC, lymphocyte percentage LYM, neutrophil percentage Neu, platelet-to-lymphocyte ratio PLR, standard deviation of red blood cell distribution width RDW _ SD, and red blood cell number RBC, wherein 108 samples are severe and 131 samples are mild. Fig. 9 is a ROC curve for alarming the infection degree of the novel coronavirus by using the white blood cell count WBC, the lymphocyte percentage LYM%, the platelet-to-lymphocyte ratio PLR, and the standard deviation of red blood cell distribution width RDW _ SD, and it can be seen from fig. 9 that the alarm effect by using the lymphocyte percentage LYM% alone is AUC 0.84, which is better. FIG. 10 is a ROC curve for warning of the extent of infection of a novel coronavirus using a linear combination of LYM% and RDW _ SD, where AUC is 0.9 and the linear combination of LYM% and RDW _ SD is, for example, -0.0857 + Lym% +0.1337 RDW _ SD-3.5294. Fig. 11 is a ROC curve for warning of the extent of infection of a novel coronavirus using a nonlinear combination of Neu% and RBC, where AUC is 0.85, and the formula for the nonlinear combination of Neu% and RBC is:

0.5705*Neu％-9.1627*RBC-0.0037*Neu％.^2+0.039*Neu％*RBC+0.6265*RBC.^2-7.9552。

in some embodiments, the alert information related to the novel coronavirus infection comprises alert information for prompting a trend of development of the novel coronavirus infection of the blood sample to be tested. For example, when the analysis parameter satisfies a third preset condition, displaying an alarm message for prompting the development trend of the novel coronavirus infection of the blood sample to be tested on a display device of the blood analyzer. That is, the blood sample analyzer provided by the embodiment of the present invention can also assist medical staff in predicting the course of disease of a patient diagnosed with the novel coronavirus, i.e., can alarm the prognosis of the novel coronavirus infection. In the embodiment of the present invention, poor prognosis means that the diseased animal may die or cannot be completely cured due to critical illness or no effective treatment method, and the production performance or economic value is affected; good prognosis means that the disease condition is light, the individual condition of the sick animal is good, the sick animal can be cured according to the full, the health can be recovered, and the production performance and the economic value are not influenced. In this case, the test blood sample is preferably a blood sample of a patient infected with the novel coronavirus.

In the case where the blood analyzer provided by the embodiment of the present invention is used for alarming for prognosis of a novel coronavirus infection, it is particularly advantageous that the analysis parameter includes at least one of the following blood conventional parameters or a combination parameter of a plurality of the following blood conventional parameters: a red blood cell distribution width parameter (e.g., red blood cell distribution width standard deviation), a macrocytic ratio, a microcytic ratio, a platelet to lymphocyte ratio, a platelet distribution width parameter (e.g., platelet distribution width and platelet distribution width standard deviation), a macrocytic ratio, a mean platelet volume, a high fluorescence intensity cell percentage, a mean red blood cell hemoglobin concentration. Preferably, the analysis parameter comprises a large platelet ratio. In some embodiments, the analysis parameters comprise a combination parameter, in particular a linear combination parameter, of the percentage of cells with high fluorescence intensity and a red blood cell distribution width parameter, in particular a red blood cell distribution width standard deviation. In some embodiments, the analysis parameter comprises a combination, in particular a linear combination, of a macrocytic proportion, a mean platelet volume and a mean corpuscular hemoglobin concentration. In still other embodiments, the analysis parameters comprise a combination of a fraction of microcytes and a platelet distribution width parameter, in particular a platelet distribution width standard deviation, in particular a non-linear combination parameter.

As shown in fig. 12 to 15, the inventors studied the efficacy of prognosis alarm on 52 samples positive for new coronavirus infection by using one or a combination of parameters of red blood cell distribution width standard deviation RDW _ SD, macrored blood cell ratio MicroRBC, microcytic ratio MicroRBC, platelet-to-lymphocyte ratio PLR, platelet distribution width PDW, platelet distribution width standard deviation PDW _ SD, macroplatelet ratio P _ LCR, mean platelet volume MPV, percentage of high fluorescence intensity cells HFC, and mean hemoglobin concentration MCHC, wherein 23 samples with poor prognosis and 29 samples with good prognosis were obtained. Fig. 12 is a ROC curve for carrying out a novel prognosis warning of coronavirus infection by using the platelet-to-lymphocyte ratio PLR, the platelet distribution width PDW, the large platelet ratio P _ LCR, and the high fluorescence intensity cell percentage HFC% alone, respectively, and it can be seen from fig. 12 that the warning effect of using the large platelet ratio P _ LCR alone is that AUC is 0.83, which is a good effect. Fig. 13 is a ROC curve for prognosis warning of novel coronavirus infection using a linear combination of HFC% and RDW _ SD, where AUC is 0.83 and the combined formula of HFC% and RDW _ SD is, for example, 2.2388 HFC% +0.4138 RDW _ SD-6.1972. Fig. 14 is a ROC curve for prognosis warning of novel coronavirus infection using a linear combination of MCHC, macrombcr% and MPV, wherein AUC is 0.86 and the combination formula of MCHC, macrombcr% and MPV is, for example, -0.0374 MCHC-0.4008 macrombcr% +0.8149 MPV + 5.8068. Fig. 15 is a ROC curve for prognosis alarm of novel coronavirus infection using nonlinear combination of MicroRBC% and PDW _ SD, where AUC is 0.85, and the nonlinear combination formula of MicroRBC% and PDW _ SD is as follows:

0.1303*MicroRBC％-4.69*PDW_SD-0.2429*MicroRBC％.^2+0.1432*MicroRBC％*PDW_SD+0.2166*PDW_SD.^2+22.3023。

an embodiment of the present invention further provides a blood analysis method for alarming a sample infected with a new coronavirus according to a blood general parameter, as shown in fig. 16, where the blood analysis method 200 includes the following steps:

s210, providing a blood analyzer;

s220, sucking a blood sample to be detected by a sampling distribution device of the blood analyzer;

s230, mixing a part of the blood sample to be detected and a treatment reagent in at least one reaction cell of the blood analyzer to prepare a sample liquid to be detected;

s240, detecting the blood cells in the sample liquid to be detected in a detection device of a blood analyzer to obtain blood conventional parameters;

s250, obtaining analysis parameters related to the novel coronavirus infection from the blood conventional parameters of the blood sample to be detected;

and S260, displaying information related to the novel coronavirus infection on a display device of the blood analyzer when the analysis parameters meet preset conditions.

In some embodiments, after the blood sample sucking step S220 and before the sample liquid to be tested step S230, the method further comprises: the sample distribution device divides the blood sample to be tested into at least two parts. For example, the sample distribution device divides the blood sample to be tested into a first blood sample portion, a second blood sample portion, and optionally a third blood sample portion.

Here, the step S230 of preparing the sample liquid to be measured includes: mixing the first part of blood sample with a leukocyte reagent to prepare a first sample liquid to be detected for detecting a leukocyte parameter; mixing the second part of the blood sample with a red blood cell reagent to prepare a second sample solution to be tested for detecting red blood cell parameters; mixing the first portion of the blood sample, the second portion of the blood sample or the third portion of the blood sample with a hemoglobin reagent to prepare a third test sample solution for detecting a hemoglobin parameter. That is, the third test sample liquid and the first test sample liquid may be prepared using the same portion of the blood sample, or the third test sample liquid and the second test sample liquid may be prepared using the same portion of the blood sample, or the first, second, and third test sample liquids may be prepared using different portions of the blood sample, respectively.

Here, the blood routine parameter detecting step S240 includes: detecting the first sample liquid to be detected in an optical detection part of a blood analyzer to obtain a leukocyte parameter and optionally a platelet parameter; detecting the second sample liquid to be detected in an impedance detection part of the blood analyzer to obtain red blood cell parameters and platelet parameters; and detecting the third sample solution to be detected in a colorimetric detection part of the blood analyzer to obtain a hemoglobin parameter.

In some embodiments, the step of obtaining leukocyte parameters comprises: the leukocytes in the first sample liquid to be measured are counted and classified in an optical detection section of a blood analyzer. For example, the leukocyte parameters include at least leukocyte count, neutrophil number and proportion, lymphocyte number and proportion, monocyte number and proportion.

For other embodiments of the blood analysis method 200 provided by the present invention, reference may be made to the above description of the blood analyzer 100 provided by the embodiments of the present invention, and details are not repeated herein.

An embodiment of the present invention further provides a computer-readable storage medium applied to a blood analyzer, where the computer-readable storage medium stores a computer program, and the computer program is executed by a processor to implement the following steps: obtaining blood conventional parameters of a blood sample to be detected, which are detected by a detection device of a blood analyzer; obtaining analysis parameters related to the novel coronavirus infection from blood conventional parameters of the blood sample to be tested; when the analysis parameters satisfy a preset condition, indicating to display information related to the novel coronavirus infection on a display device of the blood analyzer.

For other embodiments of the computer-readable storage medium provided by the present invention, reference may be made to the above description of the blood analyzer 100 and the blood analysis method 200 provided by the embodiments of the present invention, which are not repeated herein.

The individual features or combinations of features described in the individual embodiments of the description, the figures and the claims can be combined with one another in any desired manner, insofar as they are meaningful and not mutually inconsistent within the scope of the embodiments of the invention. The details, features and advantages described for the blood analyzer 100 provided with embodiments of the present invention apply in a corresponding manner to the blood analysis method 200 and the computer-readable storage medium provided with embodiments of the present invention, and vice versa.

The foregoing are merely exemplary embodiments of the present invention to enable those skilled in the art to understand or practice the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A blood analyzer, comprising:

a sampling device which is provided with a pipette nozzle and a driving part, wherein the driving part is used for driving the pipette to quantitatively suck a blood sample to be measured through the pipette nozzle;

a sample preparation device having at least one reaction cell for receiving a blood sample to be tested drawn by the sampling device and a reagent supply portion that supplies a treatment reagent to the at least one reaction cell, so that the blood sample to be tested drawn by the sampling device and the treatment reagent supplied by the reagent supply portion are mixed in the reaction cell to prepare a sample liquid to be tested;

the detection device is used for detecting the sample liquid to be detected prepared by the sample preparation device so as to obtain blood conventional parameters;

display means for displaying information relating to blood routine parameters; and

a control apparatus comprising a processor and a storage medium storing a computer program, wherein the control apparatus is configured to perform the following steps when the computer program is executed by the processor:

obtaining analysis parameters related to the novel coronavirus infection from the blood routine parameters of the blood sample to be tested,

2. A blood analyzer, comprising:

display means for displaying information relating to blood routine parameters;

a mode setting device for setting a blood routine detection mode or a novel coronavirus infection detection mode; and

3. A blood analyzer according to claim 1 or 2, wherein the analysis parameters comprise at least two blood routine parameters, in particular a combined parameter, e.g. a linear or non-linear combined parameter, of at least two blood routine parameters.

4. The blood analyzer of any one of claims 1 to 3, wherein the reagent supplying portion includes a first reagent supplying portion for supplying a leukocyte reagent, a second reagent supplying portion for supplying an erythrocyte reagent, and a third reagent supplying portion for supplying a hemoglobin reagent;

the detection device includes:

an optical detection section for detecting a first sample liquid to be tested prepared from a part of the blood sample to be tested and the leukocyte reagent supplied from the first reagent supply section to obtain a leukocyte parameter and optionally a platelet parameter,

an impedance detecting section for detecting a second sample liquid to be tested prepared from a part of the blood sample to be tested and the red blood cell reagent supplied from the second reagent supplying section to obtain a red blood cell parameter and a platelet parameter,

a colorimetric detection unit for detecting a third sample liquid to be measured prepared from a part of the blood sample to be measured and the hemoglobin reagent supplied from the third reagent supply unit to obtain a hemoglobin parameter;

wherein the analysis parameter comprises at least one of a white blood cell parameter, a red blood cell parameter, a platelet parameter and a hemoglobin parameter, or the analysis parameter comprises a combination of a plurality of parameters selected from the group consisting of a white blood cell parameter, a red blood cell parameter, a platelet parameter and a hemoglobin parameter.

5. A blood analyser according to any one of claims 1 to 4 wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: white blood cell count, neutrophil percentage, lymphocyte percentage, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, erythrocyte distribution width variation coefficient, erythrocyte distribution width standard deviation, erythrocyte number, macrocyte ratio, microcyte ratio, platelet distribution width standard deviation, average platelet volume, macrocyte ratio, high fluorescence intensity cell percentage, average erythrocyte hemoglobin concentration;

preferably, the analysis parameter comprises at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: the ratio of the neutrophils to the lymphocytes, the percentage of the lymphocytes, the variation coefficient of the distribution width of the erythrocytes, the standard deviation of the distribution width of the erythrocytes and the percentage of cells with high fluorescence intensity.

6. A blood analyser according to any one of claims 1 to 5 wherein the analysis parameter comprises at least one red blood cell distribution width parameter or the analysis parameter comprises a combination of at least one red blood cell distribution width parameter and at least one further blood routine parameter;

preferably, the erythrocyte distribution width parameter comprises the variation coefficient of the erythrocyte distribution width and the standard deviation of the erythrocyte distribution width.

7. The blood analyzer of any one of claims 1-6, wherein the alarm information related to the novel coronavirus infection comprises alarm information for prompting that the blood sample to be tested is a positive sample of the novel coronavirus infection.

8. A blood analyser according to claim 7 wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: white blood cell count, lymphocyte percentage, neutrophil to lymphocyte ratio, erythrocyte distribution width coefficient of variation.

9. The hematology analyzer of claim 8, wherein the analysis parameter includes a red blood cell distribution width coefficient of variation; and/or

The analysis parameters include a combination of a neutrophil to lymphocyte ratio and a red blood cell distribution width coefficient of variation of the red blood cell distribution width.

10. The blood analyzer of any one of claims 1-9, wherein the alarm information related to the novel coronavirus infection comprises alarm information for indicating a degree of the novel coronavirus infection of the blood sample to be tested.

11. A blood analyzer according to claim 10, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: white blood cell count, lymphocyte percentage, neutrophil percentage, platelet to lymphocyte ratio, red blood cell distribution width standard deviation, red blood cell number.

12. The hematology analyzer of claim 11, wherein the analysis parameter includes a percentage of lymphocytes; and/or

The analysis parameters comprise a combination parameter of lymphocyte percentage and standard deviation of erythrocyte distribution width, in particular a linear combination parameter; and/or

The analysis parameters comprise a combination of the percentage of neutrophils and the number of erythrocytes, in particular a non-linear combination.

13. The blood analyzer of any of claims 1-12, wherein the alert information related to the new coronavirus infection comprises alert information for prompting a trend of the new coronavirus infection of the blood sample to be tested.

14. A blood analyzer according to claim 13, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: red blood cell distribution width standard deviation, large red blood cell ratio, small red blood cell ratio, platelet-to-lymphocyte ratio, platelet distribution width standard deviation, large platelet ratio, average platelet volume, high fluorescence intensity cell percentage, and average red blood cell hemoglobin concentration.

15. The blood analyzer of claim 14, wherein the analysis parameter includes a large platelet ratio; and/or

The analysis parameters comprise combination parameters of high fluorescence intensity cell percentage and erythrocyte distribution cloth width standard deviation, in particular linear combination parameters; and/or

The analysis parameters comprise combination parameters, in particular linear combination parameters, of the proportion of macrocytes, the mean platelet volume and the mean corpuscular hemoglobin concentration; and/or

The analysis parameters comprise combination parameters of the proportion of the microcytic cells and the standard deviation of the distribution width of the platelets, in particular nonlinear combination parameters.

16. The blood analyzer of any of claims 10-15, wherein the blood sample to be tested is derived from a patient infected with a novel coronavirus.

17. A blood analyser according to any one of claims 1 to 16 wherein the control is configured so as when the computer program is executed by the processor to perform the steps of:

and controlling the display device to display the blood routine parameters of the blood sample to be tested, particularly the blood routine parameters for acquiring analysis parameters related to the novel coronavirus infection.

18. A method of blood analysis comprising:

providing a blood analyzer;

sucking a blood sample to be tested by a sampling distribution device of a blood analyzer;

mixing a part of the blood sample to be tested with a treatment reagent in at least one reaction cell of a blood analyzer to prepare a sample liquid to be tested;

detecting blood cells in the sample liquid to be detected in a detection device of a blood analyzer to obtain blood conventional parameters;

obtaining analysis parameters related to the novel coronavirus infection from blood conventional parameters of the blood sample to be tested;

and when the analysis parameters meet preset conditions, displaying information related to the novel coronavirus infection on a display device of the blood analyzer.

19. Method according to claim 18, wherein the analysis parameters comprise at least two blood routine parameters, in particular a combined parameter, such as a linear or non-linear combined parameter, of at least two blood routine parameters.

20. The method of claim 18 or 19, wherein after the blood sample to be tested is drawn by a sample dispensing device of a hematology analyzer, the method further comprises: the sampling distribution device divides the blood sample to be detected into at least two parts;

wherein, the step of preparing the sample liquid to be detected comprises the following steps:

mixing the first part of the blood sample to be tested with a leukocyte reagent to prepare a first sample solution to be tested,

mixing the second part of the blood sample to be tested with the red blood cell reagent to prepare a second sample solution to be tested,

mixing a part of the blood sample to be detected with a hemoglobin reagent to prepare a third sample solution to be detected;

wherein, the blood routine parameter detection step comprises:

detecting the first sample liquid to be tested in an optical detection part of the blood analyzer to obtain a leukocyte parameter and optionally a platelet parameter,

detecting the second sample solution to be detected in an impedance detection part of the blood analyzer to obtain a red blood cell parameter and a platelet parameter,

detecting the third sample solution to be detected in a colorimetric detection part of the blood analyzer to obtain a hemoglobin parameter;

21. The method of claim 20, wherein the step of obtaining leukocyte parameters comprises:

counting and classifying leukocytes in the first sample liquid to be tested in an optical detection part of a blood analyzer;

wherein the leukocyte parameters at least include leukocyte count, neutrophil number and proportion, lymphocyte number and proportion, and monocyte number and proportion.

22. The method according to any one of claims 18 to 21, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: the ratio of the neutrophils to the lymphocytes, the percentage of the lymphocytes, the variation coefficient of the distribution width of the erythrocytes, the standard deviation of the distribution width of the erythrocytes and the percentage of cells with high fluorescence intensity.

23. The method according to any one of claims 18 to 21, wherein the analysis parameter comprises at least one red blood cell distribution width parameter or the analysis parameter comprises a combination parameter of at least one red blood cell distribution width parameter and at least one further blood routine parameter;

24. The method of any one of claims 18 to 23, wherein the alerting step comprises:

and when the analysis parameters meet a first preset condition, displaying alarm information for prompting that the blood sample to be detected is a novel coronavirus infection positive sample on a display device of the blood analyzer.

25. The method according to claim 24, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: white blood cell count, lymphocyte percentage, neutrophil to lymphocyte ratio, erythrocyte distribution width variation coefficient;

preferably, the analysis parameter comprises a coefficient of variation of the width of the red blood cell distribution, and/or the analysis parameter comprises a combined parameter of the ratio of the neutrophil to lymphocyte and the coefficient of variation of the width of the red blood cell distribution.

26. The method of any one of claims 18 to 25, wherein the alerting step comprises:

and when the analysis parameters meet a second preset condition, displaying alarm information for prompting the infection degree of the novel coronavirus of the blood sample to be detected on a display device of the blood analyzer.

27. The method according to claim 26, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: white blood cell count, lymphocyte percentage, neutrophil percentage, platelet to lymphocyte ratio, red blood cell distribution width standard deviation, red blood cell number;

preferably, the analysis parameters comprise a percentage of lymphocytes, and/or the analysis parameters comprise a combination parameter of a percentage of lymphocytes and a standard deviation of a red blood cell distribution width, in particular a linear combination parameter, and/or the analysis parameters comprise a combination parameter of a percentage of neutrophils and a red blood cell number, in particular a non-linear combination parameter.

28. The method of any one of claims 18 to 27, wherein the alerting step comprises:

and when the analysis parameters meet a third preset condition, displaying alarm information for prompting the development trend of the novel coronavirus infection of the blood sample to be detected on a display device of the blood analyzer.

29. The method according to claim 28, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combined parameter of a plurality of the following blood routine parameters: red blood cell distribution width standard deviation, large red blood cell ratio, small red blood cell ratio, platelet-to-lymphocyte ratio, platelet distribution width standard deviation, large platelet ratio, average platelet volume, high fluorescence intensity cell percentage, average red blood cell hemoglobin concentration;

preferably, the analysis parameter comprises a large platelet ratio, and/or the analysis parameter comprises a combination parameter of the percentage of cells with high fluorescence intensity and the standard deviation of the red blood cell distribution width, in particular a linear combination parameter, and/or the analysis parameter comprises a combination parameter of the proportion of large red blood cells, the mean platelet volume and the mean red blood cell hemoglobin concentration, in particular a linear combination parameter; and/or the analysis parameter comprises a combination parameter of the proportion of microcytes and the standard deviation of the distribution width of platelets, in particular a non-linear combination parameter.

30. The method of any one of claims 18 to 29, further comprising:

displaying blood routine parameters of the blood sample to be tested on a display device of a blood analyzer, in particular displaying the blood routine parameters for obtaining analysis parameters related to the novel coronavirus infection.

31. A computer-readable storage medium for use in a blood analyzer, the computer-readable storage medium having a computer program stored thereon, the computer program when executed by a processor implementing the steps of:

obtaining blood conventional parameters of a blood sample to be detected, which are detected by a detection device of a blood analyzer;

when the analysis parameters satisfy a preset condition, indicating to display information related to the novel coronavirus infection on a display device of the blood analyzer.